title: [An advanced metastatic breast cancer patient successfully treated with combination therapy including docetaxel, doxorubicin and cyclophosphamide (TAC) as salvage therapy].
abstract: We reported here a case of advanced breast cancer successfully treated with combination therapy including docetaxel, doxorubicin and cyclophosphamide (TAC) as salvage therapy. A 56-year-old male was referred to our hospital for treatment of recurrent metastatic breast cancer. When he was admitted, his general condition was poor due to massive intraperitoneal metastasis. We administered TAC chemotherapy (docetaxel 75 mg/m(2), doxorubicin 50 mg/m(2), and cyclophosphamide 500 mg/m(2), every 3 weeks). During chemotherapy, he showed no major adverse effects except grade 3 neutropenia, which could be easily managed with G-CSF administration. Metastatic lesions almost disappeared after 4 cycles of TAC. TAC therapy was considered to be acceptable as salvage therapy for a metastatic male breast cancer patient.
authors.affiliation: Fourth Dept. of Internal Medicine, Sapporo Medical University School of Medicine, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Sato
authors.forename: Tetsuji
authors.initials: T
authors.lastname: Takayama
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Sagawa
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Kumiko
authors.initials: K
authors.lastname: Okamoto
authors.forename: Shou
authors.initials: S
authors.lastname: Takahashi
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Abe
authors.forename: Satoshi
authors.initials: S
authors.lastname: Iyama
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Murase
authors.forename: Junji
authors.initials: J
authors.lastname: Kato
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Niitsu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001943:Breast Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D000077143:Docetaxel; D004317:Doxorubicin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D016879:Salvage Therapy; D043823:Taxoids / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D017211:Treatment Failure
chemical_list: D014408:Biomarkers, Tumor; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide